Form 4: Odyssey Therapeutics Executive Insider Stock Conversion

Interim CMO Anthony W. Opipari converted preferred stock and exercised warrants in conjunction with the company's IPO.

Summary

• Anthony W. Opipari, Interim Chief Medical Officer and EVP of Translational Medicine, reported the conversion of multiple series of preferred stock into common stock.
• The conversions of Series A, B, C, and D preferred stock occurred immediately prior to the company's initial public offering.
• The reporting person exercised warrants for common stock on a net exercise basis, resulting in the acquisition of 541 shares after withholding 4 shares for tax/exercise costs.
• The reporting person was granted two new stock option tranches totaling 277,980 shares with an exercise price of $18.00.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing related to an IPO, reflecting standard executive equity adjustments rather than a change in company outlook.

Positives

• The conversion of preferred stock into common stock simplifies the company's capital structure post-IPO.
• The granting of performance-based stock options aligns executive incentives with a $1.5 billion market capitalization milestone.

Negatives

• The issuance of new stock options at $18.00 creates potential future dilution for existing shareholders.

Risks

• Vesting of 27,777 options is contingent upon the company achieving a market capitalization of at least $1.5 billion.
• Continued service requirements for option vesting create key-person dependency risks.

Future Outlook

The company is transitioning into a post-IPO environment with executive compensation tied to long-term market capitalization growth.

Management Comments

• The reporting person holds the position of Interim Chief Medical Officer and Executive Vice President, Translational Medicine.

Industry Context

StockSavvy.ai notes that this filing reflects standard post-IPO cleanup of capital structures and the implementation of long-term incentive plans common in the biotechnology sector.

Comparison to Industry Standards

• The use of performance-based vesting tied to market capitalization is a standard practice for high-growth biotech firms.
• Net exercise of warrants is a common mechanism to minimize cash outlay for executives during IPO transitions.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution from the new option grants.
• The conversion of preferred stock removes liquidation preferences associated with those series.

Next Steps

• Vesting of the first installment of the 250,203 share option grant on June 7, 2026.
• Monitoring of the company's market capitalization to determine if the $1.5 billion performance milestone is met.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, IPO, Stock Options, Biotech